When Surbhi Sarna was a teenager dealing with painful ovarian cysts, she came face-to-face with a troubling gap in modern medicine. Doctors could treat her condition, but tools for detecting ovarian cancer early were limited, often invasive, and carried the risk of harming the ovaries. That experience stayed with her and later became the foundation of a mission to build a safer, more effective way to detect the disease. Combining her training in molecular biology with entrepreneurial ambition, the Indian-origin founder went on to create nVision Medical, a startup focused on early cancer detection that eventually reached a valuation of $275 million and offered new hope in the fight against one of the deadliest cancers affecting women.
Surbhi Sarna’s journey from teenage health struggles to a scientific mission
During her teenage years, Sarna dealt with recurring ovarian cysts, a condition that can sometimes mask symptoms of more serious diseases like ovarian cancer. This exposed her to the uncertainty patients face when diagnostic tools are limited. At the time, early detection of ovarian cancer was particularly difficult, as symptoms are often vague and existing screening methods lack precision.She recognised that many women were diagnosed only at advanced stages, when treatment options are limited and survival rates drop significantly. This understanding shaped her mission to create a diagnostic solution that could detect cancer earlier and more accurately without harming reproductive health.Sarna pursued molecular biology at the University of California, Berkeley, where she gained a strong understanding of cellular biology, disease mechanisms, and diagnostic limitations. During this time, emerging research suggested that many ovarian cancers may originate in the fallopian tubes rather than the ovaries. This insight would later become central to her work.In 2012, Sarna joined Draper University. The programme focuses on turning ideas into scalable startups and provides her with mentorship, exposure to investors, and an entrepreneurial ecosystem.Here, she refined her concept into a viable business model and began building her product, bridging the gap between scientific research and real-world application.
The breakthrough behind nVision Medical
At nVision Medical, Sarna developed a fibre-optic device designed to access the fallopian tubes through a minimally invasive procedure. This marked a shift from traditional diagnostic approaches, which often rely on imaging or invasive surgeries that may not detect early-stage cancer effectively.The device allows doctors to collect cellular samples directly from the fallopian tubes, where many ovarian cancers are now believed to begin. By targeting this area, the technology improves the chances of detecting abnormalities at an earlier stage, when treatment is more effective.The device received clearance from the U.S. Food and Drug Administration, confirming that it met established standards for safety and effectiveness. This milestone enabled the technology to move into clinical settings and strengthened its credibility within the medical community.
A $275 million milestone
In 2018, nVision Medical was acquired by Boston Scientific in a deal valued at up to $275 million. The acquisition reflected the strong potential of the technology and its relevance in addressing a major unmet need in women’s healthcare.It also allowed the innovation to scale globally, reaching more patients and healthcare providers.Ovarian cancer remains one of the most difficult cancers to detect early. Symptoms are often subtle, and there is no widely effective screening method, which means many cases are diagnosed late.Each year, approximately 200,000 women die from ovarian cancer worldwide. Early detection significantly improves survival rates, making innovations like Sarna’s especially important. By focusing on the fallopian tubes, her approach aligns with evolving scientific understanding and offers a new pathway for earlier diagnosis.Surbhi Sarna’s journey shows how personal experience can drive meaningful innovation. Rather than accepting the limitations she encountered as a patient, she chose to address them through science and entrepreneurship.
